As of June 3, 2025, Amylyx Pharmaceuticals Inc (AMLX) reports a Forward P/E of N/A.
Forward P/E gauges the price investors pay for each dollar of anticipated earnings, offering insight into a stock's future valuation.
Comparing Amylyx Pharmaceuticals Inc's Forward P/E to Peers
To better understand Amylyx Pharmaceuticals Inc's position, it's useful to compare its Forward P/E against industry peers. Below are selected comparisons:
| Company | Forward P/E |
|---|---|
| Amylyx Pharmaceuticals Inc (AMLX) | - |
| Catalent Inc (CTLT) | 55.81 |
| Eli Lilly and Co (LLY) | 33.87 |
| Zoetis Inc (ZTS) | 26.44 |
| Elanco Animal Health Inc (ELAN) | 15.61 |
| Johnson & Johnson (JNJ) | 14.50 |
Compared to its competitors, Amylyx Pharmaceuticals Inc's Forward P/E is difficult to compare due to insufficient data.